GI (Gastrointestinal)

NRG – AO22102 at https://clinicaltrials.gov/study/NCT05677490?term=NCT05677490&rank=1

NCT05677490

Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for the first -line treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma

Cancer Type: FIRST-LINE TREATMENT OF METASTATIC HER2-NEGATIVE GASTROESOPHAGEAL ADENOCARCINOMA

Principal Investigator: Dr. Jon S. DuBois

Please contact Clinical Trials Office for more details: 561-263-5791

A0022101 at https://clinicaltrials.gov/study/NCT05673148?term=NCT05673148&rank=1

NCT05673148

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASUR)

Cancer Type: Pathologically proven diagnosis of colorectal adenocarcinoma with metastases (biopsy from primary tumor or metastatic site is acceptable).

No known microsatellite instable (MSI) tumor.

No known BRAF V600E mutation.

Principal Investigator: Dr. Shanel Bhagwandin

Please contact Clinical Trials Office for more details: 561-263-5791